Introduction
Obesity is a state of excess fat accumulation that is causally related to serious medical illnesses and economic burden on society. It is a leading preventable cause of death worldwide.
According to a global estimate by the World Health Organization (WHO), in 2005 there were about 1.6 billion overweight persons aged 15 years and above and among them at least 400 million adults were obese. 1 The WHO further projects that by 2015, approximately 2-3 billion adults will be overweight and more than 700 million will be obese.
1 Hypertension is one of the most common obesity-related complications, and about 30% of hypertensive individuals can be classified as being obese. 2 Results from the Framingham Study have shown that high blood pressure and overweight are both independent risk factors for cardiovascular diseases. 3, 4 In INTERSALT study 5 , the relationship between body mass index (BMI) and blood pressure was studied in over 10,000 men and women, between 20 and 59 years of age, sampled from 52 centres around the world. In this large study population, BMI was significantly associated with systolic and diastolic blood pressure.
Weight loss has been recommended for the obese hypertensive patient. Behavioral therapy alone has limited success in providing significant and sustained weight loss, which prompted us to conduct this study. Even a modest weight loss produces a positive effect on obesity-related complications including hypertension. If only anti-obesity drug treatment is adequate enough to normalize blood pressure, the cost and potential adverse affects of drug therapy can be avoided.
II. Materials and Methods
The study was conducted in department of General Medicine, King George's Medical University, Lucknow, India between August 2008-October 2009. The study was a prospective randomized open blinded evaluation (PROBE) design.
Patients between 20 to 60 years of age with body mass index > 23 with essential hypertension with diastolic blood pressure between 90 to 100 mmHg, who were not on any antihypertensive treatment were selected for this study.
Patients with endocrinal disorders, renal or hepatic disease, malignancy, medications known to alter blood pressure,body weight or appetite, pregnant and lactating women ,severely ill patients and patients not giving consent were excluded from the study Detailed history regarding complaints, duration, drugs being presently taken, any previous history of hypertension, diabetes mellitus, smoking status, family history of hypertension was carefully elicited in all cases.
A detailed clinical examination was carried out in all the cases. Blood pressure (left arm sitting position), weight, body mass index and waist/hip rate was measured carefully. Following investigations were carried out: 1. Hemogram 2. Urine: Routine and microscopic 3. Blood sugar: Fasting and postprandial 4. Serum urea and creatinine 5. Serum lipid profile Cases were randomly categorized into 2 groups: Group I: This group received Orlistat 120 mg twice daily. Group II: This group received placebo twice daily. A similar dietary chart and dietary advice (hypo-caloric diet -600 kcal/day deficit) was given to both groups.
Patients were continued on these therapies for three months. Compliance to the drugs was assessed by pill counting. Serial monitoring of weight and blood pressure was done at one month interval in all the cases. Blood sugar, fasting lipid profile and waist hip ratio was re-measured at the end of three month. Occurrence of any side effects were carefully noted.
The statistical analysis was performed using SPPS version 16.0 software. Mean weight and blood pressure in the two groups were compared using student t test. The descriptive values below 5% (p < 0.05) were considered statistically significant.
III. Results
A total of 68 patients were included in the intent to treat (ITT) analysis. The baseline parameters and findings on initial investigations in these patients are summarized in Table1. These patients were followed up for a period of three months. Weight and blood pressure was monitored monthly. The mean reduction of weight, blood pressure (systolic and diastolic) during follow up in the two groups are summarized in Table 2 and depicted graphically in Fig.1 At baseline (day 0), there was no significant difference in mean weight and blood pressure in the two groups. During follow up of three months significant reduction of these parameters was observed in group I as compared to group II evident from the first follow up visit.
At the end of three months, there was a significant change in mean weight with Orlistat (2.6%) as compared to placebo (0.3%) (-2.44 kg versus 0.33 kg ).
Figure 1: Weight reduction during follow up in the two groups
Mean systolic blood pressure was reduced to a significantly greater degree with Orlistat(3.1%) compared to placebo (1%) (-4.5 mm Hg versus -1.47 mm Hg, p <0.05) at the end of three months. Similarly, reductions in mean diastolic blood pressure was greater with Orlistat (2.8%) than with placebo (1%) (-2.66 mm Hg versus -0.97 mmHg; p < 0.05)at the end of three months of therapy.
Blood sugar (fasting and postprandial), fasting lipid profile and waist hip ratio was re-measured at the end of three months. The mean reduction of blood sugar, fasting lipid profile and waist hip ratio during follow up in the two groups are summarized in Table 3 . As evident from table 3, at baseline (day 0), there was no significant difference in these parameters in the two groups. During follow up period of three months, group I showed significantly more reduction in blood sugar, lipid profile and waist hip ratio as compared to group II.
The most common adverse effect observed in group I patients included oily stool (37.5%), diarrhoea (18.8%), nausea (18.8%) and vomiting (12.7%).The proportion of diarrhoea and oily stool were found to be significantly (p<0.05) higher in group I as compared to group II.
IV. Discussion
This study evaluates the effect of Orlistat, a lipase inhibitor, on blood pressure in overweight /obese hypertensive individuals. In conjunction with a reduced-calorie diet, treatment with 120 mg of Orlistat twice daily for 90 days significantly decreased blood pressure (systolic and diastolic), weight, blood sugar(fasting and postprandial) ,fasting lipid profile and waist hip ratio as compared to placebo.This effect is probably due to the decrease in the absorption of fat and its associated calories. 6 Gastrointestinal tract adverse effects were observed more frequently with Orlistat. Group I
Group II
In previous studies, Orlistat has been shown to cause significant and sustained reduction in weight, blood pressure, blood sugar, lipid profile and waist hip ratio in overweight or obese adults when given at a dose of 120 mg 3 times daily and combined with a mildly reduced-calorie diet for a longer duration of at least one year. 7, 8, 9 In the current study, Orlistat in a lesser dose of 120mg twice daily for a lesser time (three months) was associated with a statistically significant decrease in blood pressure, weight, blood sugar, lipid profile and waist hip ratio in contrast to the placebo group. In this three months trial, Orlistat did not raise any safety issues, and the adverse event profiles except for gastrointestinal tract adverse events as compared to placebo group.
V. Conclusion
We conclude that Orlistat 120 mg twice daily for 90 days, in conjunction with a reduced-calorie diet, significantly improves blood pressure and other cardiovascular risk factors in obese hypertensive patients and should be recommended in every obese hypertensive patient so that the cost and potential adverse affects of lifelong antihypertensive therapy can be avoided.
